402 related articles for article (PubMed ID: 28049896)
1. [Development of Molecular Probes Based on Iron Oxide Nanoparticles for in Vivo Magnetic Resonance/Photoacoustic Dual Imaging of Target Molecules in Tumors].
Sano K
Yakugaku Zasshi; 2017; 137(1):55-60. PubMed ID: 28049896
[TBL] [Abstract][Full Text] [Related]
2. In Vivo HER2-Targeted Magnetic Resonance Tumor Imaging Using Iron Oxide Nanoparticles Conjugated with Anti-HER2 Fragment Antibody.
Ding N; Sano K; Kanazaki K; Ohashi M; Deguchi J; Kanada Y; Ono M; Saji H
Mol Imaging Biol; 2016 Dec; 18(6):870-876. PubMed ID: 27351762
[TBL] [Abstract][Full Text] [Related]
3. Development of anti-HER2 fragment antibody conjugated to iron oxide nanoparticles for in vivo HER2-targeted photoacoustic tumor imaging.
Kanazaki K; Sano K; Makino A; Shimizu Y; Yamauchi F; Ogawa S; Ding N; Yano T; Temma T; Ono M; Saji H
Nanomedicine; 2015 Nov; 11(8):2051-60. PubMed ID: 26238078
[TBL] [Abstract][Full Text] [Related]
4. Sensitive Photoacoustic/Magnetic Resonance Dual Imaging Probe for Detection of Malignant Tumors.
Ding N; Sano K; Kanazaki K; Shimizu Y; Watanabe H; Namita T; Shiina T; Ono M; Saji H
J Pharm Sci; 2020 Oct; 109(10):3153-3159. PubMed ID: 32679213
[TBL] [Abstract][Full Text] [Related]
5. Development of Gold Nanorods Conjugated with Radiolabeled Anti-human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody as Single-Photon Emission Computed Tomography/Photoacoustic Dual-Imaging Probes Targeting HER2-Positive Tumors.
Ding N; Sano K; Shimizu Y; Watanabe H; Namita T; Shiina T; Ono M; Saji H
Biol Pharm Bull; 2020; 43(12):1859-1866. PubMed ID: 33268703
[TBL] [Abstract][Full Text] [Related]
6. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
[TBL] [Abstract][Full Text] [Related]
7. Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes.
Alric C; Hervé-Aubert K; Aubrey N; Melouk S; Lajoie L; Même W; Même S; Courbebaisse Y; Ignatova AA; Feofanov AV; Chourpa I; Allard-Vannier E
J Nanobiotechnology; 2018 Feb; 16(1):18. PubMed ID: 29466990
[TBL] [Abstract][Full Text] [Related]
8. Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles.
Dassler K; Roohi F; Lohrke J; Ide A; Remmele S; Hütter J; Pietsch H; Pison U; Schütz G
Invest Radiol; 2012 Jul; 47(7):383-91. PubMed ID: 22659596
[TBL] [Abstract][Full Text] [Related]
9. Probing and Enhancing Ligand-Mediated Active Targeting of Tumors Using Sub-5 nm Ultrafine Iron Oxide Nanoparticles.
Xu Y; Wu H; Huang J; Qian W; Martinson DE; Ji B; Li Y; Wang YA; Yang L; Mao H
Theranostics; 2020; 10(6):2479-2494. PubMed ID: 32194814
[No Abstract] [Full Text] [Related]
10. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-Labeled Iron Oxide Nanoparticles for Dual-Contrast (T1/T2) Magnetic Resonance and Dual-Modality Imaging of Tumor Angiogenesis.
Xue S; Zhang C; Yang Y; Zhang L; Cheng D; Zhang J; Shi H; Zhang Y
J Biomed Nanotechnol; 2015 Jun; 11(6):1027-37. PubMed ID: 26353592
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu targeted delivery of a nanoprobe enables dual photoacoustic and fluorescence tomography of ovarian cancer.
Xi L; Satpathy M; Zhao Q; Qian W; Yang L; Jiang H
Nanomedicine; 2014 Apr; 10(3):669-77. PubMed ID: 24269306
[TBL] [Abstract][Full Text] [Related]
13. Dual in vivo photoacoustic and fluorescence imaging of HER2 expression in breast tumors for diagnosis, margin assessment, and surgical guidance.
Maeda A; Bu J; Chen J; Zheng G; DaCosta RS
Mol Imaging; 2014; 13():. PubMed ID: 25430722
[TBL] [Abstract][Full Text] [Related]
14. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
Daldrup-Link HE; Meier R; Rudelius M; Piontek G; Piert M; Metz S; Settles M; Uherek C; Wels W; Schlegel J; Rummeny EJ
Eur Radiol; 2005 Jan; 15(1):4-13. PubMed ID: 15616814
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.
Lin R; Huang J; Wang L; Li Y; Lipowska M; Wu H; Yang J; Mao H
Biomater Sci; 2018 May; 6(6):1517-1525. PubMed ID: 29652061
[TBL] [Abstract][Full Text] [Related]
16. Polyethyleneimine-mediated synthesis of superparamagnetic iron oxide nanoparticles with enhanced sensitivity in T2 magnetic resonance imaging.
Do MA; Yoon GJ; Yeum JH; Han M; Chang Y; Choi JH
Colloids Surf B Biointerfaces; 2014 Oct; 122():752-759. PubMed ID: 25194592
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Testing of Modular Dual-Modality Nanoparticles for Magnetic Resonance and Multispectral Photoacoustic Imaging.
Bogdanov AA; Dixon AJ; Gupta S; Zhang L; Zheng S; Shazeeb MS; Zhang S; Klibanov AL
Bioconjug Chem; 2016 Feb; 27(2):383-90. PubMed ID: 26603129
[TBL] [Abstract][Full Text] [Related]
18. Multispectral Photoacoustic Imaging of Tumor Protease Activity with a Gold Nanocage-Based Activatable Probe.
Liu C; Li S; Gu Y; Xiong H; Wong WT; Sun L
Mol Imaging Biol; 2018 Dec; 20(6):919-929. PubMed ID: 29736563
[TBL] [Abstract][Full Text] [Related]
19. Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors.
Wu SC; Chen YJ; Wang HC; Chou MY; Chang TY; Yuan SS; Chen CY; Hou MF; Hsu JT; Wang YM
Theranostics; 2016; 6(1):118-30. PubMed ID: 26722378
[TBL] [Abstract][Full Text] [Related]
20. Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.
Satpathy M; Wang L; Zielinski R; Qian W; Lipowska M; Capala J; Lee GY; Xu H; Wang YA; Mao H; Yang L
Small; 2014 Feb; 10(3):544-55. PubMed ID: 24038985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
